CytomX Therapeutics (CTMX) Free Cash Flow (2014 - 2026)

CytomX Therapeutics has reported Free Cash Flow for 13 years, with the latest figure at -$25.5 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 20.73% year-over-year to -$25.5 million; the trailing twelve-month figure through Mar 2026 stood at -$80.2 million (up 1.29% YoY), and the FY2025 full-year result was -$75.8 million, up 12.1% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$25.5 million, down from -$23.4 million in the prior quarter.
• The five-year high for Free Cash Flow was $9.3 million in Q1 2023, with the low at -$42.0 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$20.9 million across 5 years, with a median of -$21.2 million in 2025.
• The largest YoY upside for Free Cash Flow was 122.12% in 2023 against a maximum downside of 14080.5% in 2023.
• CytomX Therapeutics' Free Cash Flow stood at $159000.0 in 2022, then plunged by 14080.5% to -$22.2 million in 2023, then gained by 11.44% to -$19.7 million in 2024, then decreased by 19.09% to -$23.4 million in 2025, then dropped by 8.98% to -$25.5 million in 2026.
• The last three Free Cash Flow figures came in at -$25.5 million (Q1 2026), -$23.4 million (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.